Glycogen storage disease due to acid maltase deficiency, also called Pompe disease, is a rare condition that causes glycogen to build up in muscles and can weaken the heart and breathing muscles. It can begin in infancy, childhood, or adulthood, and the early symptoms of glycogen storage disease due to acid maltase deficiency may include poor feeding, low muscle tone, trouble climbing stairs, or shortness of breath. Not everyone will have the same experience. In infants, glycogen storage disease due to acid maltase deficiency is often severe and can be life threatening without treatment, while later-onset disease often progresses more slowly over many years. Treatment usually includes enzyme replacement therapy, along with breathing support, physical therapy, and regular follow-up to help people living with glycogen storage disease due to acid maltase deficiency manage symptoms and stay as well as possible.
How many people live with Glycogen storage disease due to acid maltase deficiency?
This condition, more often called Pompe disease, is estimated to affect about 5,000 to 10,000 people worldwide (National Organization for Rare Disorders, 2023). In the United States, commonly used patient-group estimates suggest roughly 1,500 to 2,500 people are living with Pompe disease, although this is an estimate rather than a direct count (National Pompe Association, 2024).
Overview
Glycogen storage disease due to acid maltase deficiencySymptoms
In glycogen storage disease due to acid maltase deficiency, common signs include weak muscles, poor muscle tone, breathing problems, and trouble feeding or gaining weight in babies. Later-onset disease often causes tiring easily, trouble climbing stairs, and shortness of breath.
Outlook and prognosis
Outlook in glycogen storage disease due to acid maltase deficiency varies by age and how strongly the muscles, breathing, and heart are affected. Earlier diagnosis and treatment can slow progression and help many people maintain daily activities longer.
Causes and risk factors
Glycogen storage disease due to acid maltase deficiency is caused by changes in the GAA gene, usually inherited from both parents. Family history raises risk, while age, lifestyle, and environment do not cause it but can affect severity and complications.
Genetic influences
Genetics are central to Glycogen storage disease due to acid maltase deficiency. It is caused by changes in the GAA gene, and different variants can shape when symptoms start, how severe they are, and whether other family members may be affected.
Diagnosis
Diagnosis of glycogen storage disease due to acid maltase deficiency usually starts with the pattern of muscle weakness or breathing problems and a physical exam. Blood tests, enzyme testing, genetic tests, and sometimes muscle imaging or biopsy help confirm it.
Treatment and drugs
Treatment for glycogen storage disease due to acid maltase deficiency often centers on enzyme replacement therapy, given by infusion. Many also benefit from physical therapy, breathing support, and heart monitoring. Care is tailored to age, symptoms, and disease severity.
Symptoms
Everyday life with Glycogen storage disease due to acid maltase deficiency, also called Pompe disease, can involve weak or easily tired muscles, making feeding, lifting, walking, or even breathing more of an effort. In babies, the early features of Glycogen storage disease due to acid maltase deficiency may include marked floppiness, feeding trouble, breathing problems, and sometimes a very enlarged heart, while older children and adults more often develop gradually worsening muscle weakness and shortness of breath. Features vary from person to person and can change over time.
Babies with Glycogen storage disease due to acid maltase deficiency may feel unusually floppy when held and may have trouble holding up the head. This low muscle tone can make rolling, sitting, and other early movements harder to learn.
Older children and adults often have weakness in the hips, legs, trunk, and shoulders. Climbing stairs, standing from a chair, lifting objects, or walking long distances can become difficult.
Infants and children may be late to roll over, sit, crawl, or walk. Some may tire quickly during play because their muscles cannot keep up.
Weak breathing muscles can cause shortness of breath, fast breathing, or trouble clearing mucus. Some people first notice morning headaches, restless sleep, or daytime sleepiness because breathing becomes shallow during sleep.
How people usually first notice Glycogen storage disease due to acid maltase deficiency?
How glycogen storage disease due to acid maltase deficiency is first noticed depends a lot on the age when symptoms begin, but in babies the first signs often include weak muscle tone, trouble feeding, poor weight gain, fast breathing, and a heart that looks enlarged on an exam or ultrasound. In children or adults, it is often noticed more quietly, with climbing stairs becoming hard, frequent falls, trouble getting up from the floor, or shortness of breath, especially when lying flat or during sleep. Because these early changes can look like other muscle or breathing problems, doctors usually put the pieces together with a physical exam, blood tests, and genetic or enzyme testing.
Types of Glycogen storage disease due to acid maltase deficiency
Glycogen storage disease due to acid maltase deficiency, also called Pompe disease, does not look the same in everyone. The main variants of glycogen storage disease due to acid maltase deficiency are usually grouped by the age symptoms begin and by how much enzyme activity is left, which strongly affects severity. In practice, these variants can differ in how quickly weakness appears, whether the heart is involved, and how breathing problems show up. Not everyone will experience every feature of a given type.
Classic infantile
This form starts in the first months of life and is the most severe type of Pompe disease. Babies often have major muscle weakness, feeding trouble, poor weight gain, and a very enlarged heart that can lead to heart failure. Breathing can also become difficult early in life.
Nonclassic infantile
This type also begins in infancy, but heart problems are usually milder or may be less obvious than in the classic form. Muscle weakness and delayed motor milestones are still common, and many infants have trouble with feeding and breathing. Symptoms can progress more gradually, though it remains a serious condition.
Late-onset
This variant of glycogen storage disease due to acid maltase deficiency can begin anytime from childhood to adulthood. Many living with late-onset Pompe disease notice slowly progressive muscle weakness, often in the hips, legs, and trunk, along with shortness of breath or disturbed sleep from weak breathing muscles. Unlike infantile forms, the heart is usually not severely enlarged.
Can I slow down the onset of symptoms?
No, there is no strong evidence that lifestyle changes can meaningfully delay when symptoms start in Pompe disease, a rare inherited condition caused by a missing body enzyme. Healthy habits such as staying as active as is safely possible, getting enough sleep, eating well, and treating breathing infections quickly may help support muscle and lung health, but they have not been shown to prevent the condition or stop symptoms from appearing. If Pompe disease is found early through newborn screening or family testing, regular follow-up and enzyme replacement therapy, a treatment that replaces the missing enzyme, are well-established medical options; early care can improve outcomes for some people, but it cannot promise a later onset.
What genetics can tell you about symptoms
In glycogen storage disease due to acid maltase deficiency, also called Pompe disease, genetics can give some clues about symptoms, but they do not predict everything with certainty. Different changes in the GAA gene can affect how much enzyme activity is left, and that often influences when symptoms begin and how severe muscle weakness, trouble breathing, or feeding problems may be. In general, variants that leave very little enzyme activity are more often linked with earlier and more severe disease, while variants that allow some activity may be linked with later-onset symptoms, though even people with similar genetic changes can be affected differently.
Causes and risk factors
Changes in the GAA gene cause Glycogen storage disease due to acid maltase deficiency. These gene changes are usually inherited from both parents, and parents often have no symptoms because they are carriers. A family history of Glycogen storage disease due to acid maltase deficiency raises the chance that a child could have it. The main risk is genetic, but age, overall muscle and lung health, infections, and long periods of inactivity can affect how strongly the condition shows up. Genetic testing can sometimes clarify your personal risk.
What are the most common causes or risk factors?
This condition is caused by inherited changes in the gene that helps the body make acid maltase, an enzyme that breaks down stored sugar, so the sugar builds up in muscles and other tissues. The main risk factor is family history, especially when both parents carry one changed copy of the gene, because a child usually develops the disease only after inheriting a changed copy from each parent. There are no known lifestyle, diet, or environmental risk factors.
Environmental and biological risk factors
When people ask about risk factors for glycogen storage disease due to acid maltase deficiency, it is important to know that clear environmental causes have not been found. Non-genetic biological factors have also not been clearly linked to a higher chance of being born with it. Awareness of both biological and environmental influences helps you feel prepared, but for this condition those non-genetic influences are not well established.
For glycogen storage disease due to acid maltase deficiency, researchers have not confirmed any environmental exposure or non-genetic body-based factor that clearly raises risk. Maternal illness, routine pregnancy events, and other outside exposures have not been established as reliable causes.
Genetic risk factors
For families wondering why this condition appears in more than one relative, glycogen storage disease due to acid maltase deficiency, often called Pompe disease, is mainly caused by inherited changes in a single gene. When people ask about the genetic causes of Pompe disease, the answer usually comes back to the GAA gene. These changes reduce the activity of an enzyme that clears stored glycogen from cells, especially in muscle. Some risk factors are inherited through our genes, so risk is highest when both parents carry a disease-causing GAA variant or when the condition is already known in the family.
GAA gene: Pompe disease happens when both copies of the GAA gene carry disease-causing changes. This leaves the body with too little working enzyme to clear glycogen normally.
Recessive inheritance: Pompe disease is usually passed down in an autosomal recessive pattern. This means a child typically needs to inherit one changed GAA copy from each parent to be affected.
Carrier parents: If both parents are carriers, each pregnancy has a 25% chance of Pompe disease, a 50% chance of carrier status, and a 25% chance of inheriting neither changed copy. These odds are the same every time a pregnancy occurs.
Family history: Having a brother, sister, or other close relative with Pompe disease raises the chance that the same GAA changes are present in the family. In some cases, genetic testing can give a clearer picture of your personal risk.
Variant type: The exact pair of GAA changes can affect when Pompe disease starts and how severe it becomes. Some gene changes allow a small amount of enzyme activity, while others leave almost none.
Ancestry patterns: Certain GAA changes are seen more often in some ancestry groups, so inherited risk can be higher in some families or populations. This does not mean everyone from that background will develop Pompe disease.
Lifestyle risk factors
Lifestyle habits do not cause glycogen storage disease due to acid maltase deficiency, but they can influence muscle function, breathing, fatigue, and the risk of complications. In this condition, how lifestyle affects glycogen storage disease due to acid maltase deficiency is mainly through day-to-day symptom management and preservation of mobility and lung health. The most useful focus is on activity pacing, nutrition, respiratory support habits, and avoiding behaviors that add stress to already vulnerable muscles.
Regular, tailored exercise may help maintain strength, endurance, and joint mobility in people with acid maltase deficiency. Overexertion can worsen fatigue, trigger muscle pain, and delay recovery, so programs usually need to be individualized.
Long periods of inactivity can accelerate deconditioning, stiffness, and loss of function when muscles are already weakened. Gentle daily movement and frequent position changes may help preserve mobility and reduce secondary complications.
Eating patterns do not cause the disorder, but adequate calories and sufficient protein can support muscle maintenance and help prevent undernutrition. Large weight changes, especially weight gain, can make walking, transfers, and breathing more difficult.
Heavy meals may increase shortness of breath or discomfort in people with weakened respiratory or trunk muscles. Smaller, balanced meals can sometimes improve energy tolerance and make eating less tiring.
Risk prevention
For glycogen storage disease due to acid maltase deficiency, also called Pompe disease, true prevention of the condition itself is usually not possible because it is inherited. In practice, prevention focuses on lowering the risk of complications, slowing avoidable decline, and finding problems early. Some families may also wish to discuss genetic testing before or during pregnancy. Different people need different prevention strategies—there’s no single formula.
If Pompe disease runs in your family, genetic counseling can help you understand the chance of having an affected child. Carrier testing for relatives and reproductive planning may help some families make informed decisions.
Newborn screening or early testing after symptoms begin can help people with Pompe disease start care sooner. Early treatment may lower the risk of serious muscle weakness, feeding problems, or breathing trouble.
For many living with Pompe disease, timely enzyme replacement therapy is a key way to reduce complications. Starting treatment before major damage builds up can help protect muscle and lung function.
Regular lung checks and sleep-related breathing tests can catch weak breathing muscles early. This can help prevent serious complications such as nighttime low oxygen, chest infections, and respiratory failure.
Can you prevent Glycogen storage disease due to acid maltase deficiency?
No. Glycogen storage disease due to acid maltase deficiency is an inherited condition, so it usually cannot be prevented because people are born with the gene change that causes it. If it runs in your family, genetic counseling and carrier testing before or during pregnancy can help you understand the chances of having a child with it, but they cannot guarantee prevention.
Transmission
Glycogen storage disease due to acid maltase deficiency is not infectious, so it does not spread through the air, food, touch, sex, or blood. Instead, the genetic transmission of Glycogen storage disease due to acid maltase deficiency happens when a child inherits a nonworking copy of the gene from both parents.
Most often, each parent is an unaffected carrier, meaning they have one working copy and one changed copy of the gene. With each pregnancy, there is a 1 in 4 chance the baby will have the condition, a 1 in 2 chance the baby will be a carrier, and a 1 in 4 chance the baby will inherit neither changed copy.
When to test your genes
Consider genetic testing if newborn screening is positive, if you or your child have unexplained muscle weakness, low muscle tone, feeding trouble, or breathing problems, or if Pompe disease runs in your family. Testing can confirm the diagnosis, guide enzyme replacement therapy, and help relatives understand their own risk.
Diagnosis
People with glycogen storage disease due to acid maltase deficiency often come to medical attention because of ongoing muscle weakness, tiring more easily than expected, or breathing problems that do not have a clear cause. In babies, feeding trouble, low muscle tone, or an enlarged heart may be the first clues, while older children and adults may notice trouble climbing stairs, getting up from a chair, or shortness of breath when lying flat. Getting a diagnosis is often a turning point toward answers and support. The diagnosis of glycogen storage disease due to acid maltase deficiency is usually based on clinical features and then confirmed with specific enzyme and genetic tests.
Doctors ask about muscle weakness, fatigue, breathing symptoms, feeding problems, and when these changes began. A detailed family and health history can help show whether the pattern fits Pompe disease and whether relatives may have had similar symptoms.
The exam looks for reduced muscle strength, low muscle tone, delayed motor milestones, or signs of breathing muscle weakness. In infants, doctors also check for signs that can suggest heart involvement, which is more common in the classic early form.
Blood tests may show increased muscle enzymes such as creatine kinase, which can suggest muscle damage but do not confirm the condition on their own. Other lab tests may help rule out common conditions that can cause weakness or tiredness.
The key test measures acid α-glucosidase activity in a dried blood spot, blood sample, or skin cells. Low enzyme activity strongly supports the diagnosis of glycogen storage disease due to acid maltase deficiency and helps guide next steps.
How is Glycogen storage disease due to acid maltase deficiency diagnosed?
Doctors usually diagnose glycogen storage disease due to acid maltase deficiency, also called Pompe disease, by looking at the pattern of symptoms, such as muscle weakness, trouble breathing, and in some babies, heart problems, and then doing a test that shows the body has very low activity of the enzyme needed to break down stored sugar. They may also use blood tests and checks of the heart, muscles, and breathing to see how the condition is affecting the body, and sometimes a small muscle sample is tested. A genetic test can help confirm the diagnosis by finding a change in the gene linked to Pompe disease.
Stages of Glycogen storage disease due to acid maltase deficiency
Glycogen storage disease due to acid maltase deficiency does not have defined progression stages. This is because it is usually described by type and age of onset, such as infantile-onset or late-onset disease, rather than by a standard step-by-step pattern that everyone moves through. Different tests may be suggested to help confirm the diagnosis, including a blood test, genetic testing, and checks of enzyme activity, especially when early symptoms of glycogen storage disease due to acid maltase deficiency raise concern. Ongoing monitoring usually focuses on muscle strength, breathing, heart health in infants, and day-to-day function, because symptoms can vary widely from one person to another.
Outlook and prognosis
Outlook in glycogen storage disease due to acid maltase deficiency varies widely by age of onset and how much heart, breathing, and skeletal muscle function is affected. Untreated infantile-onset disease has the poorest prognosis, with many infants dying from cardiorespiratory failure within the first year of life, whereas early diagnosis and enzyme replacement therapy have markedly improved survival and reduced severe cardiomyopathy in many children. Late-onset disease usually progresses more slowly, but many people develop gradually worsening limb weakness and respiratory insufficiency over years to decades, sometimes requiring noninvasive ventilation or wheelchair use. Long-term prognosis is generally better when treatment starts early and is combined with respiratory, nutritional, and physical therapy support. Even with treatment, some patients continue to have residual muscle weakness, and outcomes can be influenced by factors such as CRIM status, immune response to therapy, and the degree of respiratory involvement.
Long-term effects
For many people living with glycogen storage disease due to acid maltase deficiency, the long-term picture depends a lot on when the condition starts and how severely the muscles are affected. Over time, this condition can affect movement, breathing, the heart in some infants, and day-to-day independence. Long-term effects vary widely, with some people having slowly changing weakness over many years while others have more serious health consequences earlier in life. Understanding long-term patterns can guide treatment choices.
Ongoing muscle weakness is one of the main long-term effects of glycogen storage disease due to acid maltase deficiency. Many living with this condition find that climbing stairs, getting up from a chair, lifting objects, or walking long distances becomes harder over time.
Weakness of the breathing muscles can lead to long-term shortness of breath, disturbed sleep, and lower energy during the day. In some people, breathing support may become necessary, especially at night or during illness.
Over the years, daily routines may need to change as balance, stamina, and leg strength become more limited. Some people with glycogen storage disease due to acid maltase deficiency eventually need braces, scooters, or wheelchairs for longer distances.
In infants with the classic early form, the heart can become enlarged and less able to work normally. This heart involvement is much less common in later-onset glycogen storage disease due to acid maltase deficiency.
How is it to live with Glycogen storage disease due to acid maltase deficiency?
Living with glycogen storage disease due to acid maltase deficiency, also called Pompe disease, can mean planning daily life around muscle weakness, fatigue, and, for many, breathing problems that may make walking, climbing stairs, exercising, or even sleeping feel harder than they should. The impact varies widely, but many living with Pompe disease need regular medical visits, physical therapy, breathing support, or help pacing activities so they can protect energy and stay as independent as possible. This condition often touches the whole household, because family members and caregivers may help with mobility, equipment, appointments, and emotional support, yet with treatment, rehabilitation, and good day-to-day planning, many people with Pompe disease build routines that let them stay engaged in school, work, family life, and the things that matter most.
Treatment and drugs
Glycogen storage disease due to acid maltase deficiency, also known as Pompe disease, is usually treated with regular enzyme replacement therapy, which gives the body a lab-made version of the missing enzyme so glycogen does not keep building up in muscles. This treatment can help with strength, breathing, and day-to-day function, although it does not work the same way for everyone and results often depend on age, disease severity, and how early treatment starts. Treatment plans often combine several approaches, including physical therapy, breathing support, nutrition support, and careful monitoring of the heart and lungs when needed. Some people living with glycogen storage disease due to acid maltase deficiency may also benefit from newer medicines used alongside enzyme therapy to help the enzyme work better in the body. Because early treatment tends to help most, people who notice early symptoms of glycogen storage disease due to acid maltase deficiency should talk with a specialist about the best care plan.
Can you cure Glycogen storage disease due to acid maltase deficiency?
No, glycogen storage disease due to acid maltase deficiency, also called Pompe disease, cannot currently be cured. Treatment can replace some of the missing enzyme and help with breathing, movement, strength, and day-to-day symptoms. For many people living with Pompe disease, this can slow how fast problems get worse and improve quality of life, but it does not make the condition go away.
Non-drug treatment
Living with glycogen storage disease due to acid maltase deficiency, also known as Pompe disease, often affects breathing, movement, and everyday stamina more than people expect. Treatment is not only about medicine; Supportive therapies can help preserve function, ease symptoms, and make day-to-day tasks safer and more manageable. Because symptoms vary by age and severity, care is usually tailored to the muscles and activities most affected.
Gentle strengthening, stretching, and guided aerobic activity can help many people with Pompe disease stay mobile and reduce stiffness. Not every approach works the same way, so exercise plans should be paced carefully to avoid overuse and excessive fatigue.
Breathing therapy may include airway clearance, breathing exercises, and noninvasive ventilation during sleep or naps if breathing muscles are weak. This can be especially important when early symptoms of Pompe disease include shortness of breath, restless sleep, or morning headaches.
Occupational therapy focuses on daily tasks like dressing, bathing, writing, and using the kitchen with less strain. Therapists may suggest energy-saving techniques, home changes, or hand supports to help people living with Pompe disease stay independent.
If chewing, swallowing, or speaking becomes tiring, speech-language therapy can help make eating and communication safer and easier. Some may find changes in food texture, posture while eating, and swallowing exercises helpful for preventing choking or weight loss.
Your genes may have an impact on how drugs work for you
In glycogen storage disease due to acid maltase deficiency, also called Pompe disease, the exact gene change a person is born with can sometimes affect how well treatment works, not just how severe the condition is. For example, many living with Pompe disease may respond differently to replacement enzyme treatment because some bodies are more likely to see the treatment as foreign and make blocking proteins called antibodies, which can make the medicine less helpful. This is one of the clearer cases where a person’s genetic change can help guide treatment planning and monitoring over time.
Pharmacological treatments
Daily life with glycogen storage disease due to acid maltase deficiency, also called Pompe disease, can be shaped by muscle weakness, tiring easily, and breathing problems, so treatment is aimed at slowing damage and preserving function. The main medicines used are enzyme replacement therapies, which give a lab-made version of the missing enzyme. Not everyone responds to the same medication in the same way, and the choice can depend on age, disease type, treatment history, and local approval rules. In some people, doctors also use immune-targeting medicines to reduce problems from antibodies against enzyme therapy.
Alglucosidase alfa is an enzyme replacement therapy that has been used for both infantile-onset and late-onset Pompe disease. It is given by intravenous infusion, usually every 2 weeks, and can help support survival, motor function, and breathing, although it does not cure Pompe disease.
Avalglucosidase alfa-ngpt is a newer enzyme replacement therapy used for Pompe disease and is also given by intravenous infusion, usually every 2 weeks. It is designed to improve delivery into muscle cells, and for many living with Pompe disease it is one option doctors may consider when discussing long-term treatment for late-onset Pompe disease.
Cipaglucosidase alfa is used together with miglustat, which helps stabilize the enzyme before infusion. This combination is approved in some regions for certain adults with late-onset Pompe disease, especially when response to earlier enzyme therapy has been limited or treatment goals are not being met.
Rituximab, methotrexate, and intravenous immune globulin may be used in selected infants or others at high risk of developing strong antibodies to enzyme replacement therapy. These medicines are not a replacement for the missing enzyme, but they can make treatment work better in people whose immune system reacts against it.
Genetic influences
Muscle weakness that starts in infancy, or later as trouble climbing stairs or catching your breath, in glycogen storage disease due to acid maltase deficiency usually traces back to a specific inherited gene change. This condition, also called Pompe disease, is caused by changes in both copies of the GAA gene, which leaves the body with too little of the enzyme needed to clear stored glycogen from cells. A carrier means you hold one gene change but may not have symptoms, so parents are often healthy and may not know the condition is in the family. It is passed down in an autosomal recessive pattern, meaning a child usually needs one altered copy from each parent; when both parents are carriers, each pregnancy has a 25% chance of being affected. The exact gene changes help explain why early symptoms of Pompe disease are severe in some babies, while others develop milder or later-onset disease, although the course can still vary within the same family. Testing the GAA gene can confirm the diagnosis and help relatives understand their own chances of carrying or passing on glycogen storage disease due to acid maltase deficiency.
Is Glycogen storage disease due to acid maltase deficiency genetic?
Genetics are central to Glycogen storage disease due to acid maltase deficiency. It is caused by changes in the GAA gene, and different variants can shape when symptoms start, how severe they are, and whether other family members may be affected.
Having a genetic risk is not necessarily a diagnosis
Genetic variants are a usual part of human biology and are common throughout the general population. Most do not have a direct impact on health and simply reflect natural human diversity. For many genes, carrying a variant associated with a condition suggests a possible link rather than a certain diagnosis, especially when more than one gene and environmental factors are involved. In some situations, however, a single well-understood variant in a particular gene can be enough to confirm a diagnosis.
Pharmacogenetics—how genetics influence drug effects
For many living with glycogen storage disease due to acid maltase deficiency, also called Pompe disease, treatment is shaped in part by the exact change in the GAA gene and by how much working enzyme the body can still make. Not every difference in response is genetic, but in Pompe disease, gene changes can influence when symptoms start, how quickly muscle weakness or breathing problems progress, and how soon treatment is needed. The main treatment is enzyme replacement therapy, which gives a lab-made version of the missing enzyme, and genetic results can help doctors judge how closely someone may need to be monitored. In some babies with infantile Pompe disease, certain gene patterns mean the body makes little or none of its own enzyme, which can raise the chance of an immune reaction to treatment. When that risk is high, doctors may add medicines that calm the immune system so the enzyme treatment has a better chance to work. Genetics do not predict everything, but they can help guide decisions about timing, follow-up, and what families may expect from Pompe disease treatment over time.
Interactions with other conditions
For many living with glycogen storage disease due to acid maltase deficiency, also called Pompe disease, other health problems can make day-to-day symptoms harder to manage, especially when breathing or muscle weakness is already part of daily life. Lung infections, asthma, sleep apnea, or other breathing conditions can put extra strain on already weakened breathing muscles, so a simple cold may hit harder and recovery can take longer. Heart involvement is more common in infants with Pompe disease than in adults, but when it is present, other heart conditions can further affect energy, feeding, or exercise tolerance. Doctors call it a comorbidity when two conditions occur together. In adults, problems such as scoliosis, osteoporosis, or being less mobile can add to pain, fatigue, and trouble clearing mucus from the lungs, which may raise the risk of chest infections. Because treatment and monitoring often involve several specialists, it helps to tell your care team about any new diagnosis, since medicines, anesthesia, and rehab plans may need adjusting for people with Pompe disease.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Glycogen storage disease due to acid maltase deficiency?
This condition, often called Pompe disease, can look like other problems that cause muscle weakness, low muscle tone, trouble breathing, or delayed movement, especially muscular dystrophy, spinal muscular atrophy, and other inherited muscle disorders. In babies, doctors may also need to rule out other causes of an enlarged heart or heart weakness, because those signs can overlap. The list can vary by age, since Pompe disease in infants often looks different from Pompe disease in teens or adults.
History
Doctors first recognized this condition in the early 1900s, after noticing a pattern in babies and children who developed severe muscle weakness, feeding problems, and heart enlargement. In 1932, a Dutch pathologist named Joannes Pompe described one of the earliest well-documented cases, which is why glycogen storage disease due to acid maltase deficiency is also widely known as Pompe disease. At that stage, it was identified by what happened in the body rather than by its deeper cause.
Over the years, researchers learned that Pompe disease happens when the body cannot properly break down stored glycogen inside certain cell compartments. That discovery helped explain why the condition can affect both muscles and the heart, and why some people become ill in infancy while others do not develop symptoms until later in childhood or adulthood. Early descriptions focused on the most severe cases, so the full range of Pompe disease was not appreciated at first.
As medical science evolved, doctors came to understand that late-onset Pompe disease can look quite different from the infant form, often showing up as slowly worsening muscle weakness or breathing problems rather than major heart disease. For many living with Pompe disease, this helped explain why diagnosis had sometimes been delayed for years, especially when the early symptoms of glycogen storage disease due to acid maltase deficiency resembled other muscle conditions. Researchers later identified a genetic cause, which made testing more accurate and allowed families to get clearer answers.
In recent decades, awareness has grown as screening, laboratory testing, and better clinical recognition have made it easier to identify Pompe disease across different ages. Treatment has also changed the outlook for many people, especially with the development of enzyme replacement therapy and broader use of newborn screening in some regions. The history of glycogen storage disease due to acid maltase deficiency is a good example of how medicine often moves from careful observation, to understanding the biology, to more timely diagnosis and care.